Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$64.34 USD

64.34
5,845,421

-0.55 (-0.85%)

Updated Jun 12, 2024 04:00 PM ET

Pre-Market: $64.09 -0.25 (-0.39%) 9:00 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Research for GILD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Revenue - Line of Business Segments YR Estimate12/31/202312/31/202212/31/202112/31/202012/31/2019

Product Sales: Vemlidy: Total [$M...

862842814657488

Product Sales: Yescarta: Total [$...

1,4981,160695563456

Revenue share: Symtuza: Total [$M...

529530531----

Revenues: Sofosbuvir / Velpatasvi...

1,5371,5301,4621,5991,965

Product Sales: Other HIV Total [$...

5657195407--

Product Sales: Other Hepatitis C ...

160166207193--

Product Sales: Tecartus: Total [$...

37029917644--

Revenues: Other Product: Total [$...

225253281276--

Revenues: Product: Tecartus: Othe...

1530----

Total Liver Disease: Total [$M]

2,7842,7982,850----

Total Oncology: Total [$M]

2,9322,1391,251----

Revenues: Product sales [$M]

26,93426,98227,00824,35522,119

Revenues: Royalty contract and ot...

182299297334330

Product Sales: AmBisome [$M]

492497540436407

Product Sales: HIV: Truvada [$M]

1141473711,4482,813

Product Sales: Hepatitis B virus ...

8391111185243

Product Sales: Letairis [$M]

1421962061,3762,640

Product Sales: Other [$M]

8599461,027136214

Revenues: Complera / Eviplera: To...

129200258269406

Revenues: Stribild: Total [$M]

101127189196369

Antiviral products: Ledipasvir/So...

70115212272643

Product Sales: Total HIV [$M]

18,17517,19416,31516,93816,438

Product Sales: Total HCV [$M]

1,7671,8101,8812,0642,936

Product Sales: Total Hepatitis B ...

1,017988969860--

Product Sales: Cell therapy: Tota...

1,8691,459871601--

Product Sales: Trodelvy: Total [$...

1,06368038049--

Product Sales: Total Veklury [$M]

2,1843,9055,5652,811--

Product Sales: Biktarvy: Total [$...

11,85010,3908,6247,2594,738

Product Sales: Descovy: Total [$M...

1,9851,8721,7001,8611,500

Product Sales: Genvoya: Total [$M...

2,0602,4042,8793,3383,931

Product Sales: Odefsey: Total [$M...

1,3501,4691,5681,6721,655
Revenue - Geographic Segments YR Estimate12/31/202312/31/202212/31/202112/31/202012/31/2019

Product Sales: Genvoya: Europe [$...

205284391490664

Product Sales: Genvoya: Other Int...

103136221243283

Product Sales: Descovy: Europe [$...

100118164197255

Product Sales: Odefsey: Europe [$...

294364440450438

Product Sales: Vemlidy: U.S [$M]

410429384356309

Product Sales: Vemlidy: Europe [$...

3835342921

Product Sales: Vemlidy: Other Int...

414379396272158

Product Sales: Yescarta: U.S [$M]

811747406362373

Revenue share: Symtuza: Europe [$...

133168165159130

Product Sales: Veklury: U.S [$M]

9721,5753,6402,026--

Product Sales: Veklury: Europe [$...

4087021,095607--

Product Sales: Veklury: Other Int...

8051,628830178--

Product Sales: Total HCV: Europe ...

--378413421414742

Product Sales: Total HCV: Other I...

--386392442562729

Revenues: Sofosbuvir / Velpatasvi...

859844815864971

Revenues: Sofosbuvir / Velpatasvi...

323355316337553

Revenues: Sofosbuvir / Velpatasvi...

355331331398441

Product Sales: Biktarvy: Europe [...

1,2531,103969735--

Product Sales: Biktarvy: Other In...

905777606429--

Product Sales: Descovy: Other Int...

114123139138--

Product Sales: Odefsey: Other Int...

44475250--

Product Sales: Other HIV: U.S [$M...

3715136332--

Product Sales: Other HIV: Europe ...

12243026--

Product Sales: Other HIV: Other I...

7172949--

Product Sales: Other Hepatitis C ...

104115119132--

Product Sales: Other Hepatitis C ...

--43407448--

Product Sales: Other Hepatitis C ...

--12101413--

Product Sales: Total Hepatitis B ...

418435397380--

Product Sales: Total Hepatitis B ...

--133112104409--

Product Sales: Total Hepatitis B ...

--466441468409--

Product Sales: Tecartus: U. S [$M...

24522113634--

Product Sales: Tecartus: Europe [...

110754010--

Product Sales: Yescarta: Europe [...

547355253191--

Product Sales: Yescarta: Other In...

140573610--

Product Sales: Cell therapy: U. S...

1,055968542396--

Product Sales: Cell therapy: Euro...

658430293201--

Product Sales: Cell therapy: Othe...

156603610--

Product Sales: Trodelvy: U. S [$M...

777525370380--

Product Sales: Trodelvy: Europe [...

21714310----

Product Sales: Trodelvy: Other In...

6812------

Product Sales: AmBisome: U.S. [$M...

43573961--

Product Sales: AmBisome: Europe [...

260258274230--

Product Sales: AmBisome: Other In...

189182227145--

Revenues: Other Product: Other: U...

118135136176--

Revenues: Other Product: Other: E...

406511584--

Revenues: Other Product: Other: O...

66533016--

Revenue share: symtuza: Other int...

131411----

Revenues: Product-Other HBV/HDV(6...

--725542----

Total Liver Disease: US [$M]

1,4211,4401,415----

Total Liver Disease: Europe [$M]

511525525----

Total Liver Disease: Other Intern...

852833910----

Total Oncology: US [$M]

1,8331,494912----

Total Oncology: Europe [$M]

875573303----

Total Oncology: Other Internation...

2247336----

Product Sales: HIV: Truvada: Euro...

13152227101

Product Sales: HIV: Truvada: Othe...

191835452,813

Product Sales: HIV: Viread: US [$...

8611832

Product Sales: Hepatitis B virus ...

--2223283469

Product Sales: Hepatitis B virus ...

--526272137142

Product Sales: Total HIV: Europe ...

2,1022,2192,3662,2872,312

Product Sales: Total HIV: Other i...

1,2261,1551,1211,000811

Product Sales: U.S. [$M]

19,37718,71619,17618,14116,565

Product Sales: Europe [$M]

4,1974,3424,6783,8943,567

Product Sales: Other Internationa...

3,3613,9243,1542,3201,987

Revenues: Complera / Eviplera: Eu...

70113142159214

Revenues: Complera / Eviplera: Ot...

1213142132

Revenues: Stribild: Europe [$M]

2129435475

Revenues: Stribild: Other Interna...

810141726

Antiviral products: Harvoni /Ledi...

39468492312

Antiviral products: Harvoni /Ledi...

--1217312971

Antiviral products: Harvoni /Ledi...

--195197151260

Product Sales: Biktarvy: U.S [$M]

9,6928,5107,0496,0954,225

Product Sales: Descovy: U.S [$M]

1,7711,6311,3971,5261,078

Product Sales: Genvoya: U.S [$M]

1,7521,9832,2672,6052,984

Product Sales: Odefsey: U.S [$M]

1,0121,0581,0761,1721,180

Revenue share: Symtuza: U.S [$M]

382348355331249

Revenues: Complera / Eviplera: Un...

477410289160

Revenues: Stribild: United States...

7288132125268

Product Sales: HIV: Truvada: U.S....

821133141,3762,640

Product Sales: Total HIV: US [$M]

14,84813,82012,82813,65113,315

Product Sales: Total HCV: U.S [$M...

1,0021,0051,0181,0881,465